H ypertension is common in patients with diabetes mellitus, 1, 2 and coexistence of hypertension and diabetes mellitus significantly increases the risk of atherosclerotic cardiovascular disease (ASCVD). 3 In 2017, the American College of Cardiology (ACC)/American Heart Association (AHA) published the new guideline for hypertension, 2 and the American Diabetes Association (ADA) also published a position statement for hypertension and diabetes mellitus. 4 The ACC/AHA recommended 130/80 mm Hg as the blood pressure (BP) threshold to define hypertension, whereas the ADA recommended 140/90 mm Hg. The authors of the ADA position statement emphasized the importance of an individualized approach to treat hypertension in patients with diabetes mellitus rather than changing the BP threshold. 5 Because of the difference between the 2 recommendations and lack of quality evidence to determine a precise BP threshold/target in patients with diabetes mellitus, 5 uncertainty still remains in this population. Because the clinical impact of this difference has never been studied, we investigated the prevalence and characteristics of diabetic patients with hypertension and discordant population in the United States according to the ACC/AHA and ADA recommendations.
Methods
We used data from the National Health and Nutrition Examination Survey (NHANES) 2005 to 2014, a cross-sectional survey representing the noninstitutionalized civilian population in the United States. It was conducted by the National Center for Health Statistics using a stratified, multistage probability sample design. Anonymized data are publicly available at the Centers for Disease Control and Prevention website and can be accessed at https://www.cdc.gov/nchs/nhanes/ index.htm. Between 2005 and 2014, the overall response rates ranged from 68.5% to 77.5%. NHANES was approved by the National Center for Health Statistics Research Ethics Review Board. All participants provided written informed consent.
Among 28 461 adults aged ≥20 years from the NHANES 2005 to 2014, we firstly excluded participants without 3 BP measurements (n=3483) or data on variables used to calculate 10-year ASCVD risk (n=14 174). Out of the initial candidates (n=10 804), individuals without diabetes mellitus were excluded (n=8980). Diabetes mellitus was defined as (1) a hemoglobin A 1c concentration ≥6.5%; (2) selfreported diagnosis of diabetes mellitus by a healthcare provider; or (3) self-reported use of antidiabetes mellitus medications. After these exclusions, 1824 adults with diabetes mellitus were finally included in this study. A flowchart for selection of study population is demonstrated in the Figure. BP was measured based on standardized protocol using mercury sphygmomanometer. Before the BP measurement, participants were allowed to rest for 5 minutes, and upper arm circumference was measured to guide selection of appropriate cuff size. The average of 3 BP measurements was used in this study. Hypertension was defined as (1) a BP ≥130/80 mm Hg (ACC/AHA) or ≥140/90 mm Hg (ADA) or (2) self-reported use of antihypertensive medications. Presence of ASCVD was defined based on self-reported history of coronary heart disease, angina, myocardial infarction, and stroke. The 10-year ASCVD risk scores were calculated using the pooled cohort equations based on the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. 6 Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate <60 mL/min per 1.73 m 2 , calculated using the 4-variable equation from the Modification of Diet in Renal Disease. 7 Cigarette smoking was determined based on selfreported claims of smoking every day or some days.
Statistical Analysis
We first assessed individuals who were already taking antihypertensive medications. They were considered to be receiving the The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.
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Correspondence to Doosup Shin, Department of Internal Medicine, University of South Florida Morsani College of Medicine, 17 Davis Blvd, Suite 308, Tampa, FL 33606. E-mail dshin@health.usf.edu medication appropriately based on each guideline. Then, we estimated individuals with hypertension and eligible for initiating antihypertensive drug therapy according to the ACC/AHA and ADA recommendations. We also investigated prevalence and clinical characteristics of discordant population who needs antihypertensive drug therapy based on the ACC/AHA guideline but not the ADA recommendation. Individuals in this discordant group had a BP of 130 to 139/80 to 89 mm Hg (defined as stage 1 hypertension in the ACC/AHA guideline). The analyses were repeated after being stratified by race/ethnicity (non-Hispanic white, non-Hispanic black, and Hispanic). As NHANES before 2011 did not report data for Asian separately, we could not repeat the analysis for the Asian population. All statistical analyses were performed according to the analytic guidelines of the NHANES 8 using Stata 12.1 (Stata Corp, College Station, TX). Sample weights were used to account for complex sampling design and nonresponse rate. In addition to 56.7% (95% CI, 53.4-59.9) of patients with diabetes mellitus who were already receiving antihypertensive medications, 19.7% (95% CI, 17.0-22.6) and 9.3% (95% CI, 7.5-11.5) would be eligible for initiating antihypertensive medication according to the ACC/AHA and ADA recommendations, respectively ( Table 2) . As a result, 10.4% (95% CI, 8.5-12.6) ACC indicates American College of Cardiology; ADA, American Diabetes Association; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease (coronary heart disease, angina, myocardial infarction, and stroke); CI, confidence interval; CKD, chronic kidney disease; DBP, diastolic blood pressure; HDL-C, highdensity lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; and TC, total cholesterol. SI conversion factor: to convert cholesterol to mmol/L, multiply values by 0.0259. *Age ≥65 y. †Body mass index ≥30 kg/m 2 . ‡Cigarette smoking was determined based on self-reported claims of smoking every day or some days. §Estimated glomerular filtration rate <60 mL/min per 1.73 m 2 . ‖Calculated using the pooled cohort equations based on the 2013 ACC/AHA guideline on the assessment of cardiovascular risk. ¶Ten-year predicted ASCVD risk ≥10%. Table 3 demonstrates race/ethnicity-specific prevalence of hypertension in diabetic patients and antihypertensive medication-needed population according to the ACC/AHA and ADA recommendations. The prevalence of hypertension in patients with diabetes mellitus was highest among non-Hispanic blacks regardless of BP thresholds, but the proportion of discordant population was lowest among them. Although the prevalence of hypertension in diabetic patients was lowest among Hispanics, the proportion of patients who needed initiation of antihypertensive drug therapy was highest among them.
Results

Discussion
Our study demonstrated that 76.3% (95% CI, 73.1-79.3) and 66.0% (95% CI, 62.7-69.1) of US adults with diabetes mellitus had hypertension according to the ACC/AHA and ADA recommendations, respectively. As a result, 10.4% (2.8 million) would be reclassified as having or not having hypertension based on the different BP thresholds from the 2 recent recommendations. This discordant population with a BP of 130 to 139/80 to 89 mm Hg was relatively younger and had a lower prevalence of ASCVD or CKD compared with the overall or hypertensive population with diabetes mellitus. ACC indicates American College of Cardiology; ADA, American Diabetes Association; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease (coronary heart disease, angina, myocardial infarction, and stroke); CI, confidence interval; CKD, chronic kidney disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; and TC, total cholesterol. SI conversion factor: to convert cholesterol to mmol/L, multiply values by 0.0259. *Age ≥65 y. †Body mass index ≥30 kg/m 2 . ‡Cigarette smoking was determined based on self-reported claims of smoking every day or some days. §Defined as estimated glomerular filtration rate <60 mL/min per 1.73 m 2 . ‖Calculated using the pooled cohort equations based on the 2013 ACC/AHA guideline on the assessment of cardiovascular risk.
¶Ten-year predicted ASCVD risk ≥10%.
Although ADA did not change the BP threshold/target for most of the patients with diabetes mellitus, 5 an individualized approach with a lower BP target (130/80 mm Hg) was recommended for patients at high risk of cardiovascular or kidney disease. 4, 5 When this individualized approach was applied to the discordant population, 65.9% (95% CI, 62.8-68.8) would be eligible for a lower BP target (130/80 mm Hg) based on their high 10-year ASCVD risk or coexisting conditions (ASCVD or CKD).
It should be noticed that the ACC/AHA guideline also recommended ASCVD risk assessment in all adults with hypertension, including those with diabetes mellitus, to determine the need for antihypertensive drug therapy. 2 The risk assessment is particularly important for individuals with stage 1 hypertension (BP, 130-139/80-89 mm Hg) because initiation of antihypertensive drug therapy is recommended at a BP ≥130/80 mm Hg if a 10-year ASCVD risk is 10% or greater. For convenience, the ACC/AHA guideline assumed that most adults with diabetes mellitus have a 10-year ASCVD risk ≥10% and recommended to start antihypertensive medications at BP ≥130/80 mm Hg. 2 However, our study showed that only 60.0% (95% CI, 42.6-75.2) of diabetic patients with stage 1 hypertension had a 10-year ASCVD risk ≥10%. Even after considering those with ASCVD or CKD, >30% of diabetic patients with stage 1 hypertension did not have high-risk features that would require initiation of antihypertensive drug therapy at a low BP threshold (130/80 mm Hg) per the ACC/AHA guideline. Therefore, an individualized approach with ASCVD risk assessment would be important in diabetic patients with stage 1 hypertension to determine antihypertensive treatment if the ACC/AHA guideline is strictly applied.
With discordance between the 2 recent recommendations on hypertension, controversy remains on an optimal BP threshold and target for hypertensive patients with diabetes mellitus. As discussed in the ACC/AHA guideline, this is mainly because there is limited quality evidence on this topic and no randomized trials directly demonstrated better clinical outcomes with intensive BP control <130/80 mm Hg in diabetic patients. 2, 9 Therefore, more quality studies are needed to solve this uncertainty and guide clinical practice. Furthermore, cost-benefit analysis of treating diabetic patients with stage 1 hypertension would give us additional information from public health perspective.
There are limitations in our study. First, our results rely on the accuracy and representativeness of the NHANES data for the current US population. 10 Second, BP was measured at a single visit in the NHANES. 11 Third, self-reported medical history and medication use might not be accurate.
In conclusion, application of different BP thresholds from the ACC/AHA and ADA recommendations would result in reclassification of 10.4% of US adults with diabetes mellitus as having or not having hypertension. An individualized approach with ASCVD risk assessment would be important in those discordant patients to determine antihypertensive treatment. More studies are needed to guide hypertension management in diabetic population.
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